Last $23.03 USD
Change Today -0.19 / -0.82%
Volume 489.4K
THRX On Other Exchanges
Symbol
Exchange
Munich
As of 8:10 PM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

theravance inc (THRX) Snapshot

Open
$23.17
Previous Close
$23.22
Day High
$23.25
Day Low
$22.93
52 Week High
09/20/13 - $34.52
52 Week Low
05/7/14 - $20.23
Market Cap
2.6B
Average Volume 10 Days
496.8K
EPS TTM
$-1.70
Shares Outstanding
115.0M
EX-Date
08/26/14
P/E TM
--
Dividend
$1.00
Dividend Yield
1.09%
Current Stock Chart for THERAVANCE INC (THRX)

theravance inc (THRX) Related Businessweek News

View More BusinessWeek News

theravance inc (THRX) Details

Theravance, Inc., a royalty management company, is focused on developing respiratory products. It receives royalty revenues RELVAR/BREO ELLIPTA (fluticasone furoate/vilanterol, FF/VI), ANORO ELLIPTA (umeclidinium bromide/vilanterol, UMEC/VI), and VI monotherapy through the Long-Acting Beta2 Agonist collaboration agreement with Glaxo Group Limited (GSK). The company is also entitled to a 15% interest in future payments made by GSK relating to the combination of UMEC/VI/FF and the Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program, as monotherapy, as well as in combination with other therapeutically active components, such as an inhaled corticosteroid, and other product or combination of products that might be discovered and developed under its LABA collaboration agreement with GSK. The company was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in April 2002. Theravance, Inc. was founded in 1996 and is headquartered in South San Francisco, California.

theravance inc (THRX) Top Compensated Officers

Chief Executive Officer, President, Chief Fin...
Total Annual Compensation: $515.4K
Co-Founder and Senior Vice President of Resea...
Total Annual Compensation: $485.0K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $466.7K
Chief Commercial Officer and Senior Vice Pres...
Total Annual Compensation: $457.4K
Compensation as of Fiscal Year 2013.

theravance inc (THRX) Key Developments

Theravance Inc. Announces Resignation of Bradford J. Shafer as Senior Vice President, General Counsel and Secretary

On August 21, 2014, Bradford J. Shafer indicated that he will be resigning as Senior Vice President, General Counsel and Secretary of Theravance Inc. effective August 31, 2014 in connection with his commencement of employment with Theravance Biopharma US Inc.

Theravance Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Declares Quarterly Dividend, Payable on September 18, 2014

Theravance Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported revenues of $934,000 against $1,322,000 for the same quarter a year ago. Loss from operations was $9,794,000 against $6,898,000 for the same quarter a year ago. Loss from continuing operations before income tax was $19,873,000 against $1,541,000 for the same quarter a year ago. Loss from continuing operations, net of tax was $20,151,000 or $0.18 per basic and diluted share against $1,541,000 or $0.02 per basic and diluted share for the same quarter a year ago. Net loss was $63,564,000 or $0.57 per basic and diluted share against $36,429,000 or $0.37 per basic and diluted share for the same quarter a year ago. For the six months, the company reported revenues of $154,000 against $2,644,000 for the same period a year ago. Loss from operations was $24,517,000 against $13,671,000 for the same period a year ago. Loss from continuing operations before income tax was $36,055,000 against $12,287,000 for the same period a year ago. Loss from continuing operations, net of tax was $36,333,000 or $0.33 per basic and diluted share against $12,287,000 or $0.13 per basic and diluted share for the same period a year ago. Net loss was $131,267,000 or $1.19 per basic and diluted share against $73,789,000 or $0.76 per basic and diluted share for the same period a year ago. The company Board of Directors declared a $0.25 per share dividend for the third quarter of 2014. The dividend will be paid on September 18, 2014 to all stockholders of record as of the close of business on August 28, 2014.

Theravance Inc. Announces Executive Changes, Effective August 15, 2014

Theravance Inc. announced that on August 5, 2014, the Board of Directors of the company appointed Michael W. Aguiar as President and Chief Executive Officer of the company effective August 15, 2014 and as a member of the Board of Directors effective immediately. Mr. Aguiar plans to continue to serve as Chief Financial Officer of the company until his replacement is identified and appointed. On August 6, 2014, Rick E Winningham indicated that he will be resigning as Chief Executive Officer, effective August 15, 2014 in connection with his commencement of full-time employment with Theravance Biopharma Inc. Mr. Winningham will continue to serve as Chairman of the Company's Board of Directors following his resignation as Chief Executive Officer. On August 5, 2014, the Board of Directors of the company voted to increase the current size of the board from 5 to 6 members, as permitted by the company's Amended and Restated Bylaws, and appointed Mr. Aguiar, effective immediately, to fill the vacancy created by the increase in the number of directors. Mr. Aguiar will serve as a director until the next annual meeting of stockholders, or until his successor shall have been duly elected and qualified.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
THRX:US $23.03 USD -0.19

THRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for THRX.
View Industry Companies
 

Industry Analysis

THRX

Industry Average

Valuation THRX Industry Range
No financial data is available for THRX.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact THERAVANCE INC, please visit www.theravance.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.